🇪🇺 DE-130A/DE-130A in European Union

EMA authorised DE-130A/DE-130A on 15 November 2023

Marketing authorisation

EMA — authorised 15 November 2023

  • Application: EMEA/H/C/005933
  • Marketing authorisation holder: Santen Oy
  • Local brand name: Catiolanze
  • Indication: Catiolanze is indicated for the reduction of elevated intraocular pressure (IOP) in adult patients with open angle glaucoma or ocular hypertension. Catiolanze is indicated for the reduction of elevated IOP in children from 4 years of age and adolescents with elevated IOP and paediatric glaucoma.  
  • Status: approved

Read official source →

Other Ophthalmology approved in European Union

Frequently asked questions

Is DE-130A/DE-130A approved in European Union?

Yes. EMA authorised it on 15 November 2023.

Who is the marketing authorisation holder for DE-130A/DE-130A in European Union?

Santen Oy holds the EU marketing authorisation.